The investigators propose to conduct a comparative randomized trial of 45 patients who will be recruited during their office visit at the Spaulding Rehabilitation Hospital Outpatient Center in Cambridge and/or the Massachusetts General Hospital (MGH) Spine Center in Boston. All patients with chronic LBP who elect to receive a spinal injection will be eligible to be screened for inclusion and exclusion criteria. Prior to the injection appointment in Charlestown, Massachusetts, chronic lumbar pain patients are seen by the interventional physiatrist for an examination and discussion of pain management care options. If the patient and MD determine that a spinal injection is indicated, and the patient meets the inclusion criteria, the medical assistant will hand the patient an informational flyer describing study procedures and briefly describe the study. As the study poses minimal risks and low patient time burden beyond the context of standard clinical care, the patient will indicate their wiliness to participate at the end of this clinic visit.

The patient's status will be registered in Epic and will be viewable by authorized study staff. If a consented study participant is active on gateway, the Epic Patient Reported Outcome Information System (PROMIS) measures identified could be administered via the Epic patient portal or they could be administered via iPad as per usual procedures at the injection clinic appointment in Charlestown. Upon arrival to the injection appointment in Charlestown, front desk personnel will hand study participants (flagged in the Epic record) additional paper questionnaires that are not included in the Patient Reported Outcome Measures (PROMs) PROMIS questionnaire battery but are recommended by the National Institute of Health (NIH) task force on research on chronic LBP patients or otherwise identified by the co-investigators as important to address the study aims. If the patient is not active on gateway, an iPad will be used to collect the PROMs PROMIS Epic measures upon clinic arrival. Once all measures have been collected, patients will be randomized using a computer-generated schedule that will randomly assign participants into either the control, computer delivered audiovisual intervention (AV), or the virtual reality (VR) delivered intervention.

Those patients randomized into the control group will receive usual care. After the injection, the control group will receive the anxiety measure and the pain intensity measure. These will be administered in paper format and collected by authorized study personnel. This will conclude study participation.

Study participants randomized into the audiovisual (AV) intervention group will watch and listen to a 5-minute guided relaxation session on a computer in the pre-procedure examination room prior to the injection. The injection is not part of the study procedures and is performed in a separate fluoroscopy suite. Authorized study personnel will be present in the clinic on injection days. Clinic personnel will notify study staff of the patient's randomized status. Study staff will enter the injection preparation room and make sure the patient is comfortably seated. Study staff will launch the 5-minute audiovisual presentation on a computer and leave the room. Clinic personnel will enter after the presentation is concluded and continue with standard clinic preparation for the injection. The presentation is commercially available by Provata Health. No data will be collected or identifying information provided in this process. After receiving the injection and returning to the preparation exam room, study staff will facilitate completion of the anxiety thermometer, the pain intensity measures, and a single response measure that asks if they would be interested in viewing the same presentation on their home computers. This will conclude study participation.

Those study participants randomized into the VR group will watch and listen to the same 5-minute presentation via a VR headset and smart phone. Once a study participant's status has been randomized into the VR group, study staff will enter the injection preparation room, ensure the participant is comfortably seated, orient the participant to the device, apply the headset on the participant to ensure comfort and launch the VR 5-minute presentation. Study staff will then exit the room. No data will be collected or identifying information provided during this process. The Samsung Galaxy 7s and the Samsung adaptable VR headset will be used to deliver the intervention. Clinic staff will enter the room after the 5-minute VR presentation and continue with standard clinic pre-injection procedures. After the injection and upon return to the preparation room, study staff will facilitate administration of the anxiety thermometer measure, the pain intensity measure, the virtual reality symptom questionnaire that addresses 13 symptoms that people who view VR delivered content may experience, and a single response question that asks if they would be interested in viewing the VR content on their own at home. This will conclude study participation.

The VR headset will utilize a disposable cloth face barrier and will be thoroughly cleaned with alcohol solution between patient use. A disposable hygienic face barrier will be applied to all areas of possible direct patient contact of the VR headset. This barrier is held in place by cloth straps, is hypoallergenic, and only surrounds the eyes (therefore will not affect vision or respiration). Provata health produces content that can be delivered through VR or regular delivery via a computer screen (AV). By delivering identical content in two different ways, the investigators will be able to determine if the method of delivery provides any specific advantages or disadvantages. The investigators will also be able to compare outcomes with those who received usual care.